Preimplantation Genetic Diagnosis (PGD or PIGD) is used to identify genetic defects in embryos created through in vitro fertilization (IVF) before pregnancy and can test for more than 100 different genetic conditions. The screening for specific genetic disorder or chromosomal aneuploidy before implantation avoids termination of pregnancy, and also avoids the risks of passing in on the genetic order to the child. Preimplantation genetic diagnosis is available for a large number of monogenic disorders such as single gene disorders (autosomal recessive, autosomal dominant or X-linked) or chromosomal structural aberrations (such as a balanced translocation). In some developing countries, especially in Asia, Latin America and Africa region, the use of PGD is restricted due to ethical concerns and strict regulatory norms.
The global Preimplantation genetic diagnosis testing market report estimates the market size (Revenue USD million – 2014 to 2021) for market segmentation based on diagnostic test type (aneuploidy screening, chromosomal aberrations, gender selection, HLA typing, single gene disorders, X-linked diseases, etc.), and forecasts growth trends (CAGR% – 2017 to 2021).
The global Preimplantation genetic diagnosis testing market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global Preimplantation genetic diagnosis testing market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global Preimplantation genetic diagnosis testing market and included in this report are Genesis Genetics, Genea Ltd., Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics, Inc., Reprogenetics LLC and Reproductive Genetics Institute.